Session: 12:30-14:00,
Chair: Dr. Craig Lammert
Supported by
What is new in Autoimmune Hepatitis?
Dr. Craig Lammert
Assoc. Professor of Medicine, Indiana University
The changing landscape of Primary Sclerosing Cholangitis
Dr. John Vierling
Professor of Medicine, Transplant Medical Director, Baylor College of Medicine, Houston
The patient perspective in Immune-mediated Liver disease: what do we want?
Cynthia Buness
Patient and Research advocate for PSC and Chair of Research Working Group, Global Liver Institute Pediatric and Rare Liver Disease Council, Stanford University
Learner Objectives: By the end of this session learner should be able to:
Learner Objectives:
By the end of this session, learners should be able to:
- Describe and understand the revised classification and available decision-aids in immune-mediated liver
disease, in particular Autoimmune Hepatitis (AIH) and Primary Sclerosing Cholangitis (PSC). - Critically appraise current evidence-base for precision markers in blood tests and imaging for diagnosis,
monitoring and prognosticating in patients with autoimmune liver disease. - Reflect upon patient narratives and suggestions from patient advocate groups regarding treatment strategies
and approaches to research.
Speakers:
Craig Lammert MD
Associate Professor of Medicine
University of Indiana
Craig Lammert is an Associate Professor of Medicine at Indiana University where he is a practicing adult hepatologist. His research interests are in the realm of autoimmune liver disease, primarily focused on autoimmune hepatitis (AIH). He currently serves as the Vice Chair on the Cholestatic and Autoimmune Liver Disease Special Interest Group for AASLD. Further, he has founded the Autoimmune Hepatitis Association, a patient centric organization of over 8,000 worldwide members that aims to enhance disease education, foster support and further research in the realm of AIH.
John M. Vierling MD FACP FAASLD AGAF
Professor of Medicine and Surgery, Chief of Hepatology
Baylor College of Medicine, Houston
John Vierling is tenured Professor of Medicine and Surgery and Chief of Hepatology and Director of BayloJohn M. Vierling is tenured Professor of Medicine and Surgery, Chief of Hepatology and Director of Baylor Liver Health at the Baylor College of Medicine (BCM) in Houston, Texas. He also serves as Director of Advanced Liver Therapies (a clinical research unit) and formerly served as Program Director of the Hepatology and Liver Transplantation Fellowship. He received his MD from Stanford University School of Medicine. His clinical interests include autoimmune and alloimmune liver diseases, liver transplantation, acute liver failure, viral hepatitis, metabolic-dysfunction associated steatotic liver disease (MASLD), Wilson disease and drug-induced liver injury (DILI). His translational research interest is immunologic mechanisms of hepatobiliary injury in multiple liver diseases. He has authored over 300 manuscripts and chapters and is co-editor of Liver Immunology: Principles and Practice.r Liver Health at the Baylor College of Medicine (BCM) in Houston, Texas. He also serves as Director of Advanced Liver Therapies (a clinical research unit) and formerly served as Program Director of the Hepatology and Liver Transplantation Fellowship. He received his MD from Stanford University School of Medicine.
His clinical interests include autoimmune and alloimmune liver diseases, liver transplantation, acute liver failure, viral hepatitis, metabolic-dysfunction associated steatotic liver disease (MASLD), Wilson disease and drug-induced liver injury (DILI). His translational research interest is immunologic mechanisms of hepatobiliary injury in multiple liver diseases. He has authored over 300 manuscripts and chapters and is co-editor of Liver Immunology: Principles and Practice.
Cynthia Buness JD MBA
Patient and Research Advocate for Primary Sclerosing Cholangitis
Chair of Research Working Group, Global Liver Institute Pediatric and
Rare Liver Diseases Council, Stanford University
Ms Buness has been a full-time volunteer research and patient advocate for Primary Sclerosing Cholangitis (PSC) for over 12 years. She focuses on bringing medical professionals and patients together in a collaborative effort to study and treat PSC. She helps educate patients and assists them in resolving insurance coverage issues for PSC therapies. She has co-written and/or helped design multiple grant applications for adult and pediatric PSC clinical trials both domestically and internationally. She has also co-authored eight published journal papers with doctors from Mayo Clinic, Stanford University, UCLA, Yale University, University of Queensland, University of Milano-Bicocca and other medical institutions related to PSC and oral vancomycin therapy.
Ms Buness has a JD, an MBA, and a BS in zoology with an emphasis in chemistry. She serves on Global Liver Institute Pediatric and Rare Liver Diseases Council and as Co-Chair of Research Working Group. She also is Parent Leader for Stanford University’s Autoimmune Liver Disease Network for Kids (A-LiNK), and a multi-year volunteer for National Patient Advocate Foundation. She previously served as an Advocate for the Arizona State University’s Center for the Convergence of Physical Sciences and Cancer Biology, funded by the National Institute of Health. Prior to her work as an advocate, Ms Buness was a commercial trial litigator for 14 years, specialized in complex science and insurance related matters.